- Stocks
- Healthcare
- NASDAQ: DVAX

Price (delayed)

$11.39

Market cap

$1.49B

P/E Ratio

162.71

Dividend/share

N/A

EPS

$0.07

Enterprise value

$1.61B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of

DVAX's quick ratio has soared by 66% YoY and by 9% QoQ

DVAX's gross margin is up by 26% YoY and by 2.4% QoQ

The company's gross profit has shrunk by 55% YoY but it rose by 4.2% QoQ

DVAX's EPS has plunged by 96% YoY

The net income has dropped by 96% year-on-year

What are the main financial stats of DVAX

Market
Valuations
Earnings

Shares outstanding

130.89M

Market cap

$1.49B

Enterprise value

$1.61B

Price to earnings (P/E)

162.71

Price to book (P/B)

2.41

Price to sales (P/S)

6.28

EV/EBIT

110.16

EV/EBITDA

72.58

EV/Sales

6.82

Revenue

$236.15M

EBIT

$14.62M

EBITDA

$22.19M

Free cash flow

$53.69M

Per share
Balance sheet
Liquidity

EPS

$0.07

Free cash flow per share

$0.41

Book value per share

$4.74

Revenue per share

$1.81

TBVPS

$7.56

Total assets

$986.57M

Total liabilities

$368.09M

Debt

$251.54M

Equity

$618.48M

Working capital

$795.28M

Debt to equity

0.41

Current ratio

15.2

Quick ratio

13.74

Net debt/EBITDA

5.39

Margins
Efficiency
Dividend

EBITDA margin

9.4%

Gross margin

80.3%

Net margin

3.9%

Operating margin

-10.4%

Return on assets

0.9%

Return on equity

1.5%

Return on invested capital

1.5%

Return on capital employed

1.6%

Return on sales

6.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Dynavax Technologies stock price performed over time

Intraday

1.7%

1 week

9.31%

1 month

1.61%

1 year

-19.79%

YTD

-18.53%

QTD

1.42%

How have Dynavax Technologies's revenue and profit performed over time

Revenue

$236.15M

Gross profit

$189.73M

Operating income

-$24.55M

Net income

$9.22M

Gross margin

80.3%

Net margin

3.9%

The company's operating margin has shrunk by 131% YoY but it rose by 35% QoQ

DVAX's operating income has dropped by 111% year-on-year but it is up by 34% since the previous quarter

The net income has dropped by 96% year-on-year

Dynavax Technologies's net margin has plunged by 89% YoY

What is Dynavax Technologies's growth rate over time

What is Dynavax Technologies stock price valuation

P/E

162.71

P/B

2.41

P/S

6.28

EV/EBIT

110.16

EV/EBITDA

72.58

EV/Sales

6.82

DVAX's EPS has plunged by 96% YoY

DVAX's P/B is 79% below its 5-year quarterly average of 11.1 and 18% below its last 4 quarters average of 2.9

Dynavax Technologies's equity has increased by 10% YoY

DVAX's revenue has dropped by 64% year-on-year

The P/S is 14% less than the 5-year quarterly average of 7.2 but 4.7% more than the last 4 quarters average of 5.9

How efficient is Dynavax Technologies business performance

The ROE has plunged by 97% YoY

Dynavax Technologies's ROA has plunged by 96% YoY

Dynavax Technologies's return on invested capital has shrunk by 95% YoY

DVAX's ROS has plunged by 83% YoY

What is DVAX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DVAX.

How did Dynavax Technologies financials performed over time

Dynavax Technologies's total assets is 168% higher than its total liabilities

Dynavax Technologies's current ratio has surged by 68% YoY and by 10% QoQ

DVAX's quick ratio has soared by 66% YoY and by 9% QoQ

Dynavax Technologies's debt is 59% less than its equity

Dynavax Technologies's equity has increased by 10% YoY

The debt to equity has contracted by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.